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Abstract
Halofuginone, an inhibitor of collagen synthesis, ap-
pears to be a promising antitumoral drug in preclinical
studies. We used a relevant rat model of autochtho-
nous, chemically induced, spontaneously metastasiz-
ing hepatocellular carcinoma (HCC) to test the efficacy
of halofuginone on tumor progression and matrix
metalloproteinase (MMP) expression. Following se-
quential administration of diethylnitrosamine and N-
nitrosomorpholine for 14 weeks, all animals developed
HCC and then received halofuginone or its solvent for
10 weeks. The final number of liver tumors was lower in
the halofuginonegroup than in the solvent group (57.2 ±
4.6 vs 68 ± 5.0; P < .01). The percentage of the lung
surface infiltrated by metastasis was much smaller in
the halofuginone group (0.3 ± 0.2%) than in the solvent
group (13.5 ± 10.1%; P < .02). MMP-9 activity was de-
creased in the halofuginone group by 89% and 63% in
non-neoplastic parts of the liver and tumor, respec-
tively. The percentage of active MMP-2 was reduced by
90% in non-neoplastic parts of the liver and by 61% in
tumors. This was likely subsequent to a decreased
expression of both MMP-14 and tissue inhibitor of ma-
trix metalloproteinase-2, which are required for pro–
MMP-2 activation. These results, obtained from a
clinically relevant model, further suggest the potential
benefit of halofuginone in HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of themost common
cancers [1], and its prognosis is still very poor because it is
associated, in most cases, with chronic liver disease and
has a propensity to invade the liver and to metastasize. Cu-
rative surgery or liver transplantation is rarely possible and
often leads to tumor recurrence [2]. Even if palliative treat-
ments such as radiofrequency ablation have shown some
success [3], there is still a need for new treatments, especially
for advanced tumors.
Halofuginone is an analog of a low-molecular-weight quina-
zolinone alkaloid isolated from the plant Dichroa febrifuga. It is
widely used as a coccidiostat in chickens and turkeys, and is a
potent inhibitor of collagen type a1 (I) gene expression and
extracellular matrix (ECM) deposition [4]. This effect on ECM
deposition has led to the demonstration that halofuginone has
strong antifibrotic properties in several organs, such as the liver
[5,6], skin [7], or lung [8].
Halofuginonealso inhibits tumorprogression.Thiswas shown
in models of grafted tumor cells of bladder carcinoma [9],
pheochromocytoma [10], prostate cancer [11], sarcoma [12], or
Wilms tumor [13], as well as in a model of chemically induced
bladder cancer [9]. The antitumor effect of halofuginone was
attributed to its action on several critical steps in primary tumor
progression, such as angiogenesis [9,14], stromal support [9],
and cell proliferation [9]. Moreover, halofuginone also sup-
pressed the transcription of the MMP-2 gene [10,14,15], which
is associated with a marked decrease in ECM invasion in vitro
and lung colonization by bladder carcinoma cells [15]. Very re-
cently, it was shown that halofuginone could suppress the growth
of HCC in a xenograft model [16].
The aim of the present study was to test whether halofugi-
none would have beneficial effects on tumor progression and
metastasis development in the clinically relevant setting of
established HCC in rats with chemically induced HCC.
Materials and Methods
Animals
Five-week-old male Fischer F344 rats were obtained from
Charles River (St. Aubin les Elbeuf, France) and were housed
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five per cage in an air-conditioned room at 22jC and 55%
humidity, with a 12-hour light/dark cycle for 1 week before
the beginning of the experiments. Food and tap water were
available ad libitum. The experiments were conducted ac-
cording to institutional and national guidelines for the care
and use of laboratory animals.
Experimental Protocol
HCCswere induced essentially as described by Futakuchi
et al. [17], with slight modifications. Rats were given a single
intraperitoneal injection of diethylnitrosamine (Sigma Aldrich,
St. Quentin Fallavier, France) at a dose of 100 mg/kg body
weight as initiator of liver carcinogenesis. Then, they received
80 ppm of N-nitrosomorpholine (Tokyo Kasei, Tokyo, Japan)
in drinking water for 14 weeks.
Thirty-five animals were used in this study. Twenty-five
animals were submitted to the carcinogenesis protocol de-
scribed above. On week 14, they were further divided into
three groups. Group 1 included five animals that were sacri-
ficed to check the presence of histologically confirmed
HCC. Animals in groups 2 and 3 (n = 10 per group) received
daily intraperitoneal injections of halofuginone (Collgard
Biopharmaceuticals Ltd., Petach Tikva, Israel) at a dose of
100 mg/kg body weight in 0.9% NaCl or saline only, respec-
tively, for 10 weeks.
Groups 4 and 5 were control groups of five animals each
that did not receive any carcinogen but received halofuginone
alone or solvent alone, respectively, from week 14 onward.
At the end of the experiment (week 24), surviving animals
(see Results section) were sacrificed under ketamine anes-
thesia. Two hours prior to sacrifice, animals received an intra-
peritoneal injection of 100 mg/kg bromodeoxyuridine (BrdU).
The body, liver, spleen, and lungs were weighed, and an
autopsy was performed. Liver nodules or tumors visible at
the surface of the liver and greater than 3 mm in diameter
were counted and measured. Multiple samples were taken
from tumors and from the apparently non-neoplastic portion
of the liver.
The lungs were separated into the right lobe and the
left lobe. Six plane sections of each lobe were made at
0.4-cm intervals.
Histology and Immunohistochemistry
Formalin-fixed paraffin-embedded samples were sec-
tioned at 4 mm and routinely stained with hematoxylin and
eosin.
BrdU staining was performed as previously described
[18]. Stained hepatocyte nuclei were counted in 10 random
fields using 20 objective. Blood vessels were immuno-
stained using an antibody to von Willebrand factor (Abcam,
Cambridge, UK).
Quantification of Lung Infiltration with Metastasis
Lung sections stained with hematoxylin and eosin were
photographed with a digital camera (EDAS 120; Kodak,
Rochester, NY). The total area of the section was measured
with ImageJ software (http://rsb.info.nih.gov/ij). The sections
were examined under a Zeiss Axioplan 2 microscope (Carl
Zeiss Microscopy, Jena, Germany). Images were acquired
with the Zeiss MC 80 DX AxioCam (Carl Zeiss Vision, Hall-
bergmoos, Germany) by means of the Axiovision image pro-
cessing and analysis system (Carl Zeiss Vision). The surface
area of metastatic nodules was obtained using a comput-
erized image analysis system (KS300; Carl Zeiss Vision).We
could thus calculate for each section the percentage of the
section occupied by metastasis. The mean percentage ± SD
of all sections for a given animal was calculated and used as
an indicator of metastasis burden.
Gelatin Zymography
Gelatin zymography was performed essentially as de-
scribed by Musso et al. [19]. Sixteen-micrometer cryostat sec-
tions were solubilized in 25 ml of 10% glycerol and 1% sodium
dodecyl sulfate (SDS) at room temperature for 15 minutes.
Protein concentration was estimated from A280 readings.
Twenty microliters of samples normalized for protein
concentration was electrophoresed on a 10% SDS polyacryl-
amide gel containing 1 mg/ml gelatin. After washing with
2.5% Triton X-100, the gel was incubated overnight at 37jC
in 50 mM Tris–HCl, pH 8, supplemented with 5 mM CaCl2.
Gels were finally stained for 15 minutes in 40% methanol/
10% acetic acid containing 0.25% Coomassie brilliant blue
and destained in H2O. Proteolytic activity was detected as a
white zone in a dark blue field.
For quantitative purposes, gel pictures were acquired
with a digital camera as above, and the intensity of proteolytic
bands was measured using the Kodak 1D 3.0 USB software.
Results were expressed in arbitrary units.
Real-Time Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Total RNA was extracted from liver samples following
grinding in liquid nitrogen, using the RNeasy Mini kit (Qiagen,
Courtaboeuf, France). Transcripts of MMP-2, MMP-9, MMP-
14, and tissue inhibitor of matrix metalloproteinase-2 (TIMP-
2) were quantified by a method of quantitative RT-PCR,
which has previously been described in detail [20]. Each
sample was normalized based on its expression of the
RPLP0 gene (also known as 36B4, encoding acidic ribo-
somal phosphoprotein P0).
Statistical Analysis
All data were expressed as mean ± SD. Mann-Whitney
test and one-way analysis of variance (ANOVA) were per-
formed using the Statcrunch package (www.statcrunch.com).
When required, post hoc Tukey’s test was applied following
ANOVA (www.cvgs.k12.va.us/DIGSTATS/Imain.html). Sur-
vival data were analyzed with log-rank test. Results were
considered to be significant when P < .05.
Results
In preliminary experiments, we found that every animal that
submitted to this protocol developed histologically confirmed
HCC by the 14th week of treatment (Figure 1A). These tu-
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mors were highly vascularized, as shown by von Willebrand
factor immunostaining (Figure 1B). After week 14 and until
the death of the animals, the tumors increased in size and
number. On week 24, every surviving animal had lung meta-
static nodules (Figure 1C).
Vital Parameters
From week 14 onward, control animals kept gaining weight
steadily, whereas carcinogen-treated animals did not. Halo-
fuginone treatment had no adverse effects on the weight curve
in either control or carcinogen-treated animals (Figure 2A). At
the time of sacrifice, the mean body weight was marginally,
but not significantly, higher in halofuginone-treated rats com-
pared to controls (302.0 ± 9.0 vs 290.0 ± 15.6 g).
No death occurred in animals that did not receive carcin-
ogens. Halofuginone treatment delayed the onset of mor-
tality in animals bearing HCCs because the first death
occurred on week 7 posttreatment versus week 4 in controls.
The final survival rate on week 24 reached 50% and 40% in
halofuginone and control groups, respectively. The difference
was not significant (Figure 2B).
Liver Tumors
At the time of sacrifice, the livers of all animals were
infiltrated with a large number of tumors, making the precise
assessment of tumor mass impossible. We thus used two
indirect estimates. First, we quantified the number of nodules
(with a diameter > 3 mm) that were detectable at the surface
of the liver. In four surviving solvent-treated animals, there
were 68.0 ± 5.0 nodules, whereas there were only 57.2 ±
4.6 nodules in five remaining halofuginone-treated animals
(P < .01, Mann-Whitney test; Figure 3A). Small nodules may
Figure 1. Histology of tumors. (A) Liver tumor from a solvent-treated animal,
stained with hematoxylin – eosin – saffron. (B) Immunostaining for von
Willebrand factor in a liver tumor showing intense staining. (C) Lung metas-
tasis from a solvent-treated animal, stained with hematoxylin –eosin–saffron.
Figure 2. Vital parameters. (A) Growth curve of animals. The curves begin
on week 14, the time at which all animals bear HCCs and treatment with
halofuginone or its solvent begins. Open symbols refer to animals that did not
receive any carcinogens, whereas closed symbols refer to carcinogen-treated
HCC-bearing animals. Standard deviations are not represented for the sake of
clarity and were always < 12% of the mean. (B) Survival curve. This was also
plotted starting from the beginning of treatment on week 14. The graph shows
data only for HCC-bearing animals because there was no death in animals
that did not receive carcinogens.
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include actual HCCs with prenoplastic lesions. However, in
our preliminary experiments, we found that nodules larger
than 6mm in diameter on week 24 were always HCCs.When
we counted only nodules > 6 mm in diameter, the average
number was 23.3 ± 2.9 in control animals and only 16.8 ± 4.0
in animals treated with halofuginone (P < .02; Figure 3B). As
a second estimate of tumor mass, we measured liver weight
and the liver weight/body weight ratio. Both liver weight
(30.6 ± 1.8 vs 31.9 ± 2.5 g) and liver weight/body weight
ratio (10.1 ± 0.3% vs 11.0 ± 0.8%)were lower in halofuginone-
treated animals than in solvent-treated animals, although
the differences were not statistically significant.
No gross differences were seen on histologic examination
of liver tumors from both groups of animals. There was also
no difference in vascularity, as assessed by von Willebrand
factor staining (data not shown). Cell proliferation was mea-
sured with BrdU staining, and no significant difference was
seen between the solvent group (29.5 ± 11.3 positive hepa-
tocytes per field) and the halofuginone group (20.0 ± 11.2
positive hepatocytes per field) (Figure 4).
Lung Metastasis
The extent of lung metastasis was significantly different
between the two groups. Although metastasis was detect-
able in every animal, the percentage of the lung surface
section occupied by metastasis was 13.5 ± 10.1% in the con-
trol group (range, 1.3–29.1%) versus only 0.30 ± 0.24%
(range, 0.01–0.5%) in halofuginone-treated animals (P <
.02, Mann-Whitney test; Figure 3C).
MMP Expression and Activity
The enzymatic activity of gelatinases was measured on
solubilized frozen sections taken from experimental animals.
These activities were measured separately in tumors and in
macroscopically nontumoral areas. For comparative pur-
poses, we used tumors of similar sizes in the solvent and
halofuginone groups (about 5 mm in diameter). Samples
from control and halofuginone-treated animals were com-
pared on the same gels. MMP-2 or MMP-9 activities were
below the detection threshold in animals that did not receive
carcinogens (not shown). Figure 5 shows representative
gels, and Table 1 summarizes data concerning MMP-9 and
MMP-2 in tumor-bearing animals.
Figure 3. Tumor burden. Tumor burden was evaluated at the time of sacrifice of surviving animals (solvent group, n = 4; halofuginone group, n = 5). (A and B) Box-
and-whiskers plot of the number of nodules > 3 mm in diameter or > 6 mm, respectively. The top and bottom of each box represents the 75th and 25th percentiles,
respectively. Whiskers represent the range, and the line in the box represents the median value of the distribution. The differences between the solvent and
halofuginone groups were statistically significant in both cases using the Mann-Whitney test (P < .01 and P < .02, respectively). (C) The percentage of lung section
surface infiltrated by metastasis was quantified as described in Materials and Methods section. The difference between groups was highly significant (P < .02;
Mann-Whitney test).
Figure 4. Immunostaining for BrdU. Liver sections from solvent-treated (A) or
halofuginone-treated (B) animals were immunostained for BrdU. Positive nu-
clei appear dark. No quantitative differences were seen between the two
groups.
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A band migrating at 95 kDa and corresponding to pro–
MMP-9 was detected in every experimental sample. The
mean intensity of this band was significantly decreased in
halofuginone-treated animals, both in tumors (Figure 5A) and
in non-neoplastic parts of the liver (Figure 5B), comparedwith
solvent-treated animals. Active MMP-9 was barely detect-
able in animals receiving the solvent and was undetectable
in halofuginone-treated animals.
Regarding MMP-2, a band migrating at 66 kDa cor-
responding to pro–MMP-2 was detected in every sample,
whereas a 62-kDa band corresponding to active MMP-2
was seen in only some of them. The mean amount of MMP-
2 (pro + active) was significantly decreased in non-neoplastic
parts of the liver from halofuginone-treated animals (Fig-
ure 4B), but was similar in tumors from both groups of ani-
mals (Figure 5A). However, the percentage of active MMP-2
was much lower in halofuginone-treated animals, in tumors
(39% of the values of solvent-treated animals) (Figure 5A),
and in non-neoplastic parts of the liver (10% of the values of
solvent-treated animals; P < .01 in both cases) (Figure 5B).
Specifically, active MMP-2 was detected in non-neoplastic
parts of the liver of every solvent-treated animal, but only in
one from the halofuginone group.
A shown in Figure 5, C and D, analysis of MMP-2 and
MMP-9 transcripts by quantitative RT-PCR correlated well
with zymography experiments, although the decrease in
MMP-9 transcripts in non-neoplastic parts of the liver failed
to reach statistical significance.
Pro–MMP-2 activation is carried out at the cell surface
by a complex composed of MMP-14 (or MT1-MMP) and
TIMP-2 [21,22]. We thus measured the expression of these
two components using quantitative RT-PCR. As shown in
Figure 6, the expression of MMP-14, expressed as MMP-14/
P0 ratio, was significantly reduced by halofuginone treatment
in tumors (from 5.20 ± 1.59 to 2.47 ± 1.07) and in non-
neoplastic parts of the liver (from 6.28 ± 0.29 to 2.63 ±
1.51) compared with the solvent. The same was true for
TIMP-2, with a decrease from 11.21 ± 4.74 to 5.71 ± 4.50 in
tumors and from 16.20 ± 3.25 to 3.72 ± 1.64 in non-neoplastic
parts of the liver.
Discussion
The results of this study indicate that halofuginone had
limited effect on the growth of primary rat HCC, but greatly
decreased its metastatic potential. This is a very relevant
finding because extrahepatic metastasis is clearly becom-
ing a problem in the management of HCC patients, espe-
cially when attempts to control the primary tumor have been
performed. Whereas beneficial effects of halofuginone on
experimental tumor progression have been previously re-
ported, all studies, with a single exception [9], dealt with
grafted tumor cells in recipient animals. Our use of a highly
relevant autochthonous model of liver carcinogenesis makes
our results of special interest in a clinical perspective. More-
over, we show for the first time that halofuginone is able
to dramatically reduce spontaneous metastasis. Although
Table 1. MMP activity in the liver.









MMP-9 1437 ± 160 534 ± 381* 1249 ± 267 134 ± 47*
Total MMP-2 444 ± 87 468 ± 215 415 ± 76 60 ± 21*
Active
MMP-2 (%)
38.3 ± 2.3 15.0 ± 12.6* 28.8 ± 4.5 2.8 ± 6.2*
MMP activity was measured with gelatin zymography in liver samples from
animals surviving up to week 24.
Values are in arbitrary units and are presented as mean ± 1 SD.
*P = .01, Mann-Whitney test.
Figure 5. Expression of MMP-2 and MMP-9. (A and B) Gelatin zymography.
Tissue samples were obtained from control animals (n = 4) or halofuginone-
treated animals (n = 5). MMP activity was measured in gelatin-containing gels,
either in tumors (A) or in corresponding non-neoplastic parts of the liver from
the same animals (B). The experiment was repeated several times with
identical results. Data quantification is shown in Table 1. (C and D) Expression
of transcripts of MMP-2 and MMP-9. Transcripts of MMP-2 and MMP-9 were
assayed by quantitative PCR, and results were normalized according to the
level of the P0 gene. Results are shown as mean ± SD. MMP-2 is shown in (C)
and MMP-9 is shown in (D). ‘‘Cont’’ refers to control animals that did not
receive any carcinogens. ‘‘Solv’’ and ‘‘Halo’’ refer to animals bearing HCC that
were treated with solvent or halofuginone, respectively. Measurements were
made either in non-neoplastic parts of the liver or within tumors, as indicated.
One-way analysis of variance showed that overall results differed signifi-
cantly between groups (P < .01 for MMP-2 and P < .003 for MMP-9). Asterisks
indicate significant differences between individual groups by post hoc Tukey’s
test (P < .01).
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an antimetastatic effect of halofuginone has been pre-
viously reported, it was in a much less relevant context of
intravenous injections of a tumor cell line treated in vitro
with halofuginone [15].
Our experiments pinpoint a possible mechanism by which
halofuginone reduces tumor metastasis. Indeed, we found
that halofuginone treatment had a profound effect on MMP
expression and activity. On the first hand, halofuginone
greatly reduced the expression of pro–MMP-9 both in tumors
and in non-neoplastic parts of the liver. Although little ac-
tive MMP-9 could be detected in control animals, none was
seen under halofuginone treatment. In addition, halofugi-
none treatment led to a drastic decrease in the activation
of MMP-2 in tumors and in nontumoral liver. It has already
been shown that halofuginone could reduce MMP-2 expres-
sion likely through an inhibitory effect on the activity of the
MMP-2 promoter [10,14,15]. Decreased MMP-9 expression
has also been reported in cultured cells treated with halo-
fuginone [10], although not in vivo. Mostly, the fact that halo-
fuginone impedes MMP-2 activation has not been shown
previously. Because only the cleaved, active form of MMP-2
is proteolytically active, this could be a very significant find-
ing. The role of MMP-2 and MMP-9 in metastasis is largely
substantiated (reviewed in Egeblad and Werb [23]). Animals
with inactivation of either MMP-2 [24] or MMP-9 [25] are less
susceptible to metastasis. In addition, selective inhibition of
these two enzymes with a drug results in decreased metas-
tasis [26]. Thus, the reduced activity of these two MMPs in
liver tumors offers a plausible explanation for the beneficial
effects of halofuginone on metastasis. Additional effects of
halofuginone, notably on ECM remodeling, may also con-
tribute to the antimetastatic effect.
In the final part of our study, we sought for an explanation
to the decreased activation of MMP-2. MMP-2 is synthesized
as an inactive zymogen form and must undergo a proteolytic
cleavage of its prodomain to become catalytically active.
Pro–MMP-2 is activated at the cell surface within a com-
plex with membrane-associated MMP-14 (MT1-MMP) and
TIMP-2 [21,22]. We found that halofuginone treatment
greatly reduced the expression of the transcripts for these
two proteins. It is likely that the resulting alteration in the
stoichiometry of the complex may account for the decreased
processing of pro–MMP-2. It is noteworthy that expression
of MMP-14 and TIMP-2 is increased in human HCC [27]
and that the amount of active MMP-2 is increased in these
tumors [19]. It is thus likely that patients with HCC could
benefit from halofuginone treatment. This could be of great
significance because there are currently not many per-
spectives for these patients. In that respect, it is important
to note that halofuginone tolerance is excellent in experi-
mental animals and that human trials also point to good
tolerance [28,29].
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